Ticker Details
Akebia Therapeutics, Inc. Akebia Therapeutics Inc is a biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology.
IPO Date:	March 24, 2018
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$273.62M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.13 | 3.56%
Avg Daily Range (30 D):	$0.04 | 3.17%
Avg Daily Range (90 D):	$0.04 | 3.01%

Institutional Daily Volume
Avg Daily Volume:	2.83M
Avg Daily Volume (30 D):	4.06M
Avg Daily Volume (90 D):	3.14M

Trade Size
Avg Trade Size (Sh.):	315
Avg Trade Size (Sh.) (30 D):	347
Avg Trade Size (Sh.) (90 D):	314

Institutional Trades
Total Institutional Trades:	1,034
Avg Institutional Trade:	$1.63M
Avg Institutional Trade (30 D):	$.6M
Avg Institutional Trade (90 D):	$1.23M
Avg Institutional Trade Volume:	.48M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.55M
Avg Closing Trade (30 D):	$.53M
Avg Closing Trade (90 D):	$1.18M
Avg Closing Volume:	478.29K

News

Feb 19, 2026 @ 1:00 PM Akebia Therapeutics to Report Fourth Quarter and F... Source: Na

Feb 4, 2026 @ 1:00 PM Akebia Therapeutics to Present at the Guggenheim E... Source: Not Specified

Dec 1, 2025 @ 2:43 PM Why Is Small-Cap Q32 Bio Stock Soaring On Monday? Source: Vandana Singh

Nov 6, 2025 @ 11:30 PM Vafseo® (vadadustat) Dialysis Dependent Patient... Source: Akebia Therapeutics

Jul 8, 2025 @ 12:00 PM Akebia Therapeutics to Present at the H.C. Wainwri... Source: Mercedes Carrasco

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$-.08	$-.03	$-.05
Diluted EPS	$-.08	$-.03	$-.05
Revenue	$232.4M	$53.54M	$57.62M
Gross Profit	$188.28M	$41.25M	$45.09M
Net Income / Loss	$-20.51M	$-9.05M	$-12.24M
Operating Income / Loss	$5.29M	$-4.7M	$-8.55M
Cost of Revenue	$44.13M	$12.29M	$12.54M
Net Cash Flow	$49.29M	$-22.2M	$18.4M
PE Ratio